News Release 

Trial clarifies use of blood transfusion in anaemic heart attack patients

REALITY trial presented in a Hot Line Session today at ESC Congress 2020

European Society of Cardiology

Research News

Sophia Antipolis, France - 1 Sept 2020: Restricting blood transfusion in anaemic heart attack patients to those with very low haemoglobin levels saves blood with no negative impact on clinical outcomes. That's the finding of the REALITY trial presented in a Hot Line session today at ESC Congress 2020.1

Anaemia affects approximately 5-10% of patients with myocardial infarction and is an independent predictor of cardiac events and increased mortality. The antiplatelet and anticoagulant medications used to treat myocardial infarction raise the risk of bleeding, which in turn elevates the risk of anaemia and mortality.

However, there is uncertainty over the benefits of blood transfusion in these patients. Observational studies have reported that transfusion is associated with a higher rate of mortality in patients with myocardial infarction.2 The optimal transfusion strategy in patients with acute myocardial infarction and anaemia is also unclear. Only two very small randomised trials have been conducted, with conflicting results.3,4

REALITY is the largest randomised trial comparing a restrictive versus a liberal blood transfusion strategy in myocardial infarction patients with anaemia. In the restrictive strategy, transfusion was withheld unless haemoglobin dropped to 8 g/dL. In the liberal strategy, transfusion was given as soon as haemoglobin was 10 g/dL or below. Previous trials have compared these two strategies in other settings such as gastrointestinal bleeding, cardiac surgery or non-cardiac surgery but patients with acute myocardial infarction were excluded.

There were two primary endpoints. The primary clinical endpoint was a composite of major adverse cardiac events (MACE) at 30 days, including all-cause death, myocardial infarction, stroke, and emergency percutaneous coronary intervention (PCI) prompted by myocardial ischaemia. The cost effectiveness endpoint was the incremental cost effectiveness ratio (ICER) at 30 days.

Principal investigator Professor Philippe Gabriel Steg of Hospital Bichat, Paris, France explained the reasons for having both a clinical and cost effectiveness outcome: "Our hypothesis was that in myocardial infarction patients with anaemia, a restrictive strategy would be non-inferior to a liberal strategy with respect to clinical outcomes at 30 days but would be less costly."

The trial was conducted in 35 hospitals in France and Spain. It enrolled 668 patients with acute myocardial infarction and anaemia (haemoglobin 10 g/dL or below, but above 7 g/dL) at any time during admission. Patients were randomly allocated to the restrictive or liberal transfusion strategy and followed-up for 30 days.

The restrictive transfusion strategy was non-inferior to the liberal strategy in preventing 30-day MACE. The primary clinical outcome occurred in 36 patients (11.0%) allocated to the restrictive strategy and 45 patients (14.0%) patients allocated to the liberal strategy (difference -3.0%; 95% confidence interval [CI] -8.4% to 2.4%). The relative risk of 30-day MACE with the restrictive versus liberal strategy was 0.79.

Cost effectiveness analysis indicated that the restrictive strategy had an 84% probability of being cost-saving while improving clinical outcomes, i.e. "dominant" from a medico-economic standpoint.

Regarding safety, compared to patients receiving the liberal strategy, those allocated to the restrictive strategy were significantly less likely to develop an infection (restrictive 0.0% vs. liberal 1.5%; p=0.03) or acute lung injury (restrictive 0.3% vs. liberal 2.2%; p=0.03).

Professor Steg said: "Blood is a precious resource, and transfusion is costly, logistically cumbersome, and has side effects. The REALITY trial supports the use of a restrictive strategy for blood transfusion in myocardial infarction patients with anaemia. The restrictive strategy saves blood, is safe, and is at least as effective in preventing 30-day cardiac events compared to a liberal strategy, while saving money."

<

###

Notes to editors

Authors: ESC Press Office
Mobile: +33 (0)7 85 31 20 36
Email: press@escardio.org

The hashtag for ESC Congress 2020 is #ESCCongress.

Follow us on Twitter @ESCardioNews

Funding: Trial funded via a grant from Programme de Recherche Médico-Economique (PRME) 2015, from the French Ministry of Health; and a grant from Instituto de Salud Carlos III (the Spanish Ministry of Economy and Competitiveness), Grant nº PI15/01543.

Disclosures: Philippe Gabriel Steg discloses:

Research grants: Bayer, Merck, Servier, Sanofi.

Speaker or consultant (including steering committee, DMC and CEC memberships): Amarin, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, BristolMyersSquibb, Idorsia, Mylan, NovoNordisk, Novartis, Pfizer, Regeneron, Sanofi, Servier.

References and notes

1Abstract title: A randomized trial of liberal vs. restrictive red blood cell transfusion strategies in patients with acute myocardial infarction and anaemia.

2Chatterjee S, Wetterslev J, Sharma A, et al. Association of Blood Transfusion With Increased Mortality in Myocardial Infarction: A Meta-analysis and Diversity-Adjusted Study Sequential Analysis. JAMA Intern Med. 2013;173:132-139.

3Cooper HA, Rao SV, Greenberg MD, et al. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011;108:1108-1111.

4Carson JL, Brooks MM, Abbott JD, et al. Liberal Versus Restrictive Transfusion Thresholds For Patients With Symptomatic Coronary Artery Disease. Am Heart J. 2013;165:964-971.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress

ESC Congress is the world's largest gathering of cardiovascular professionals contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2020 takes place online from 29 August to 1 September. More information is available from the ESC Press Office at press@escardio.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.